Compositions and methods for siRNA inhibition of HIF-1 alpha
View Patent ↗RNA interference using small interfering RNAs which target HIF-1 alpha mRNA inhibit expression of the HIF-1 alpha gene. As HIF-1 alpha is a transcriptional regulator of VEGF, expression of VEGF is also inhibited. Control of VEGF production through siRNA-mediated down-regulation of HIF-1 alpha can be used to inhibit angiogenesis, in particularly in diseases such as diabetic retinopathy, age related macular degeneration and many types of cancer.
1. An isolated siRNA comprising a sense RNA strand and an antisense RNA strand, wherein the sense and an antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence substantially identical to a target sequence of about 19 to about 25 contiguous nucleotides in human HIF-1 alpha mRNA, wherein said target sequence is SEQ ID No. 223.
2. The siRNA of claim 1 , wherein the human HIF-1 alpha mRNA is SEQ ID NO: 1.
3. The siRNA of claim 1 , wherein the sense RNA strand comprises one RNA molecule, and the antisense RNA strand comprises one RNA molecule.
4. The siRNA of claim 1 , wherein the sense and antisense RNA strands forming the RNA duplex are covalently linked by a single-stranded hairpin.
5. The siRNA of claim 1 , wherein the siRNA further comprises non-nucleotide material.
6. The siRNA of claim 1 , wherein the siRNA further comprises an addition, deletion, substitution or alteration of one nucleotide.
7. The siRNA of claim 1 , wherein the sense and antisense RNA strands are stabilized against nuclease degradation.
8. The siRNA of claim 1 , further comprising a 3′ overhang.
9. The siRNA of claim 8 , wherein the 3′ overhang comprises from 1 to about 6 nucleotides.
10. The siRNA of claim 8 , wherein the 3′ overhang comprises about 2 nucleotides.
11. The siRNA of claim 4 , wherein the sense RNA strand comprises a first 3′ overhang, and the antisense RNA strand comprises a second 3′ overhang.
12. The siRNA of claim 11 , wherein the first and second 3′ overhangs separately comprise from 1 to about 6 nucleotides.
13. The siRNA of claim 12 , wherein the first 3′ overhang comprises a dinucleotide and the second 3′ overhang comprises a dinucleotide.
14. The siRNA of claim 13 , where the dinucleotide comprising the first and second 3′ overhangs is dithymidylic acid (TT) or diuridylic acid (uu).
15. The siRNA of claim 8 , wherein the 3′ overhang is stabilized against nuclease degradation.
16. An isolated retinal pigment epithelial cell comprising the siRNA of claim 1 .
17. A recombinant plasmid comprising nucleic acid sequences for expressing an siRNA comprising a sense RNA strand and an antisense RNA strand, wherein the sense and an antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence substantially identical to a target sequence of about 19 to about 25 contiguous nucleotides in human HIF-1 alpha mRNA, wherein said target sequence is SEQ ID No. 223.
18. The recombinant plasmid of claim 17 , wherein the nucleic acid sequences for expressing the siRNA comprise an inducible or regulatable promoter.
19. The recombinant plasmid of claim 17 , wherein the nucleic acid sequences for expressing the siRNA comprise a sense RNA strand coding sequence in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter, and an antisense RNA strand coding sequence in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter.
20. The recombinant plasmid of claim 19 , wherein the plasmid is pAAVsiRNA.
21. A recombinant viral vector comprising nucleic acid sequences for expressing an siRNA comprising a sense RNA strand and an antisense RNA strand, wherein the sense and an antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence substantially identical to a target sequence of about 19 to about 25 contiguous nucleotides in human HIF- 1 alpha mRNA, wherein said target sequence is SEQ ID No. 223.
22. The recombinant viral vector of claim 21 , wherein the nucleic acid sequences for expressing the siRNA comprise an inducible or regulatable promoter.
23. The recombinant viral vector of claim 21 , wherein the nucleic acid sequences for expressing the siRNA comprise a sense RNA strand coding sequence in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter, and an antisense RNA strand coding sequence in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter.
24. The recombinant viral vector of claim 21 , wherein the recombinant viral vector is selected from the group consisting of an adenoviral vector, an adeno-associated viral vector, a lentiviral vector, a retroviral vector, and a herpes virus vector.
25. The recombinant viral vector of claim 21 , wherein the recombinant viral vector is pseudotyped with surface proteins from vesicular stomatitis virus, rabies virus, Ebola virus, or Mokola virus.
26. The recombinant viral vector of claim 24 , wherein the recombinant viral vector comprises an adeno-associated viral vector.
27. A pharmaceutical composition comprising an siRNA and a pharmaceutically acceptable carrier, wherein the siRNA comprises a sense RNA strand and an antisense RNA strand, wherein the sense and an antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence substantially identical to a target sequence of about 19 to about 25 contiguous nucleotides in human HIF-1 alpha mRNA, wherein said target sequence is SEQ ID No. 223.
28. The pharmaceutical composition of claim 27 , further comprising lipofectin, lipofectamine, cellfectin, polycations, or liposomes.
29. A pharmaceutical composition comprising the plasmid of claim 17 , or a physiologically acceptable salt thereof, and a pharmaceutically acceptable carrier.
30. The pharmaceutical composition of claim 29 , further comprising lipofectin, lipofectamine, cellfectin, polycations, or liposomes.
31. A pharmaceutical composition comprising the viral vector of claim 21 and a pharmaceutically acceptable carrier.